airborne disease measles virus measles, airborne disease virus
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Cohort A (18 years or older) - No known history of measles or vaccination - Decided to take MMR vaccination before the upcoming measles outbreak Cohort B (18 years or older) - No known history of measles or vaccination (seronegative confirmed) - Contracted measles during the upcoming outbreak Cohort C (18 years or older) - No known history of measles or vaccination (seronegative confirmed) Cohort D (18 years or older) - Experienced measles during the 2013 outbreak Cohort E (18 years or older) - Received second dose of measles vaccines ±10 years ago
Exclusion criteria
Exclusion criteria: 1. Diagnosed chronic disease 2. Immune suppression (due to medication or underlying disease) 3. Additionally for subjects recruited to Cohort A: -pregnant women or women planning to get pregnant in less than one month after the start of the study. This is a precaution; the MMR vaccine is not recommended for pregnant women. -People who have had a severe allergic reaction (e.g., anaphylaxis) after a previous vaccination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the immune repertoire before and after measles. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary parameters in this study are: Comparison of humoral responses to various pathogens and the change over time in samples taken before and up until 3 years after measles in comparison to vaccination. This will also be compared 10 years after infection or vaccination Profiling of peripheral cytokines and the change over time in samples taken before and up until 3 years after measles in comparison to vaccination or participants that remain uninfected. This will also be compared 10 years after infection or vaccination. Quantifying cellular responses by flow cytometry after antigenic stimulation with a wide range of bacterial and viral pathogens and change over time in samples taken before and up until 3 years after measles, in comparison to vaccination, or participants that remain uninfected. This will also be compared 10 years after infection or vaccination. Comparison of measles-specific immunity 10 years after infection or vaccination. Correlation of above parameters to disease severity. | — |
Countries
Netherlands
Contacts
Public ContactC.H. Geurts van Kessel
Erasmus MC, Universitair Medisch Centrum Rotterdam
Outcome results
None listed